Selected research
Industry Research
Pet Cancer Therapeutics Industry Research Report 2026
Market perspective
The global Pet Cancer Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pet Cancer Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pet Cancer Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pet Cancer Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pet Cancer Therapeutics include Zoetis, Zenoaq, VetiVax, VetDC, Inc, Rhizen Pharmaceutical SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, Ngelheim International GmbH and Morphogenesis, Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pet Cancer Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pet Cancer Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pet Cancer Therapeutics Market by Company
Zoetis
Zenoaq
VetiVax
VetDC, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Ngelheim International GmbH
Morphogenesis, Inc
Merial Inc
Karyopharm Therapeutics, Inc
ELIAS Animal Health
Elanco
Boehringer Ingelheim International GmbH
Aratana Therapeutics, Inc
AB Science
Pet Cancer Therapeutics Segment by Type
Immunotherapy
Combination Therapy
Chemotherapy
Targeted Therapy
Pet Cancer Therapeutics Segment by Application
Mammary
Squamous Cell Cancer
Lymphoma
Melanoma
Mast Cell Cancer
Others
Pet Cancer Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Cancer Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pet Cancer Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Cancer Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pet Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapy
- Combination Therapy
- Chemotherapy
- Targeted Therapy
Applications
- Mammary
- Squamous Cell Cancer
- Lymphoma
- Melanoma
- Mast Cell Cancer
- Others
Companies covered
- Zoetis
- Zenoaq
- VetiVax
- VetDC, Inc
- Rhizen Pharmaceutical SA
- Regeneus Ltd.
- Oasmia Pharmaceuticals AB
- Ngelheim International GmbH
- Morphogenesis, Inc
- Merial Inc
- Karyopharm Therapeutics, Inc
- ELIAS Animal Health
- Elanco
- Boehringer Ingelheim International GmbH
- Aratana Therapeutics, Inc
- AB Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pet Cancer Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Immunotherapy
- 2.2.3 Combination Therapy
- 2.2.4 Chemotherapy
- 2.2.5 Targeted Therapy
- 2.3 Pet Cancer Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Mammary
- 2.3.3 Squamous Cell Cancer
- 2.3.4 Lymphoma
- 2.3.5 Melanoma
- 2.3.6 Mast Cell Cancer
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Pet Cancer Therapeutics Breakdown Data by Type
- 3.1 Global Pet Cancer Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Pet Cancer Therapeutics Forecasted Market Size by Type (2027-2032)
4 Pet Cancer Therapeutics Breakdown Data by Application
- 4.1 Global Pet Cancer Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Pet Cancer Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pet Cancer Therapeutics Market Perspective (2021-2032)
- 5.2 Global Pet Cancer Therapeutics Growth Trends by Region
- 5.2.1 Global Pet Cancer Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pet Cancer Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Pet Cancer Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Pet Cancer Therapeutics Market Dynamics
- 5.3.1 Pet Cancer Therapeutics Industry Trends
- 5.3.2 Pet Cancer Therapeutics Market Drivers
- 5.3.3 Pet Cancer Therapeutics Market Challenges
- 5.3.4 Pet Cancer Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pet Cancer Therapeutics Players by Revenue
- 6.1.1 Global Top Pet Cancer Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Pet Cancer Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Pet Cancer Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pet Cancer Therapeutics Head Office and Area Served
- 6.4 Global Pet Cancer Therapeutics Players, Product Type & Application
- 6.5 Global Pet Cancer Therapeutics Manufacturers Established Date
- 6.6 Global Pet Cancer Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pet Cancer Therapeutics Market Size (2021-2032)
- 7.2 North America Pet Cancer Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Pet Cancer Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pet Cancer Therapeutics Market Size (2021-2032)
- 8.2 Europe Pet Cancer Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Pet Cancer Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pet Cancer Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Pet Cancer Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pet Cancer Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pet Cancer Therapeutics Market Size (2021-2032)
- 10.2 South America Pet Cancer Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Pet Cancer Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pet Cancer Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Pet Cancer Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pet Cancer Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Zoetis
- 12.1.1 Zoetis Company Information
- 12.1.2 Zoetis Business Overview
- 12.1.3 Zoetis Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.1.4 Zoetis Pet Cancer Therapeutics Product Portfolio
- 12.1.5 Zoetis Recent Developments
- 12.2 Zenoaq
- 12.2.1 Zenoaq Company Information
- 12.2.2 Zenoaq Business Overview
- 12.2.3 Zenoaq Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.2.4 Zenoaq Pet Cancer Therapeutics Product Portfolio
- 12.2.5 Zenoaq Recent Developments
- 12.3 VetiVax
- 12.3.1 VetiVax Company Information
- 12.3.2 VetiVax Business Overview
- 12.3.3 VetiVax Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.3.4 VetiVax Pet Cancer Therapeutics Product Portfolio
- 12.3.5 VetiVax Recent Developments
- 12.4 VetDC, Inc
- 12.4.1 VetDC, Inc Company Information
- 12.4.2 VetDC, Inc Business Overview
- 12.4.3 VetDC, Inc Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.4.4 VetDC, Inc Pet Cancer Therapeutics Product Portfolio
- 12.4.5 VetDC, Inc Recent Developments
- 12.5 Rhizen Pharmaceutical SA
- 12.5.1 Rhizen Pharmaceutical SA Company Information
- 12.5.2 Rhizen Pharmaceutical SA Business Overview
- 12.5.3 Rhizen Pharmaceutical SA Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.5.4 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Product Portfolio
- 12.5.5 Rhizen Pharmaceutical SA Recent Developments
- 12.6 Regeneus Ltd.
- 12.6.1 Regeneus Ltd. Company Information
- 12.6.2 Regeneus Ltd. Business Overview
- 12.6.3 Regeneus Ltd. Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.6.4 Regeneus Ltd. Pet Cancer Therapeutics Product Portfolio
- 12.6.5 Regeneus Ltd. Recent Developments
- 12.7 Oasmia Pharmaceuticals AB
- 12.7.1 Oasmia Pharmaceuticals AB Company Information
- 12.7.2 Oasmia Pharmaceuticals AB Business Overview
- 12.7.3 Oasmia Pharmaceuticals AB Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.7.4 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Product Portfolio
- 12.7.5 Oasmia Pharmaceuticals AB Recent Developments
- 12.8 Ngelheim International GmbH
- 12.8.1 Ngelheim International GmbH Company Information
- 12.8.2 Ngelheim International GmbH Business Overview
- 12.8.3 Ngelheim International GmbH Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.8.4 Ngelheim International GmbH Pet Cancer Therapeutics Product Portfolio
- 12.8.5 Ngelheim International GmbH Recent Developments
- 12.9 Morphogenesis, Inc
- 12.9.1 Morphogenesis, Inc Company Information
- 12.9.2 Morphogenesis, Inc Business Overview
- 12.9.3 Morphogenesis, Inc Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.9.4 Morphogenesis, Inc Pet Cancer Therapeutics Product Portfolio
- 12.9.5 Morphogenesis, Inc Recent Developments
- 12.10 Merial Inc
- 12.10.1 Merial Inc Company Information
- 12.10.2 Merial Inc Business Overview
- 12.10.3 Merial Inc Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.10.4 Merial Inc Pet Cancer Therapeutics Product Portfolio
- 12.10.5 Merial Inc Recent Developments
- 12.11 Karyopharm Therapeutics, Inc
- 12.11.1 Karyopharm Therapeutics, Inc Company Information
- 12.11.2 Karyopharm Therapeutics, Inc Business Overview
- 12.11.3 Karyopharm Therapeutics, Inc Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.11.4 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio
- 12.11.5 Karyopharm Therapeutics, Inc Recent Developments
- 12.12 ELIAS Animal Health
- 12.12.1 ELIAS Animal Health Company Information
- 12.12.2 ELIAS Animal Health Business Overview
- 12.12.3 ELIAS Animal Health Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.12.4 ELIAS Animal Health Pet Cancer Therapeutics Product Portfolio
- 12.12.5 ELIAS Animal Health Recent Developments
- 12.13 Elanco
- 12.13.1 Elanco Company Information
- 12.13.2 Elanco Business Overview
- 12.13.3 Elanco Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.13.4 Elanco Pet Cancer Therapeutics Product Portfolio
- 12.13.5 Elanco Recent Developments
- 12.14 Boehringer Ingelheim International GmbH
- 12.14.1 Boehringer Ingelheim International GmbH Company Information
- 12.14.2 Boehringer Ingelheim International GmbH Business Overview
- 12.14.3 Boehringer Ingelheim International GmbH Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.14.4 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Product Portfolio
- 12.14.5 Boehringer Ingelheim International GmbH Recent Developments
- 12.15 Aratana Therapeutics, Inc
- 12.15.1 Aratana Therapeutics, Inc Company Information
- 12.15.2 Aratana Therapeutics, Inc Business Overview
- 12.15.3 Aratana Therapeutics, Inc Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.15.4 Aratana Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio
- 12.15.5 Aratana Therapeutics, Inc Recent Developments
- 12.16 AB Science
- 12.16.1 AB Science Company Information
- 12.16.2 AB Science Business Overview
- 12.16.3 AB Science Revenue in Pet Cancer Therapeutics Business (2021-2026)
- 12.16.4 AB Science Pet Cancer Therapeutics Product Portfolio
- 12.16.5 AB Science Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst